Global
About
Development milestones Mission&Vision Founder Research Achievement
Technology Platforms
Single domain antibody Five core technology platforms
PIPELINE
BUSINESS PARTNERSHIPS
Product Out-Licensing Co-Development
investor
Career development
Our Story Social Recruitment
News
Company News Media
Contact Us
Company Address Online Message
×
Our Story

Share the latest information

Our Story
News
Company News
Media
2025-03-25
Novamab Announces Successful Completion of LQ036 Phase IIa Clinical Trial Demonstrating Superior Efficacy and Safety – The World’s First Inhaled IL-4Rα Biologic Offers an Innovative Treatment Option for Asthma Patients
More
2021-03-12
Novamab has completed a round of financing of billion yuan!
More
2021-03-08
Rocky Biology has obtained the high-tech enterprise certificate!
More
2020-12-08
Novamab won two honors!
More
2020-10-16
We will work together and forge ahead - the third anniversary of the founding of Novamab
More
2020-09-17
Novamab won the recognition of high-tech enterprises in Shanghai!
More
2019-11-22
The joint research results of Novamab and Peking University Cancer Hospital in nuclear medicine were published online in the international journal BIOCONJUGATE CHEMISTRY
More
2019-10-16
Publication of research and development results of industrialized new PD-1 nanoantibody drug expressed by Pichia pastoris
More
2019-10-10
Report on the 29th ERS (European Respiratory Society Annual Conference) Conference of Loki Biology
More
2019-07-27
Don't forget your original intention and move forward courageously -- and Loqi 2019 Mid-Year Summary and Commendation Conference
More
2019-04-11
LQ036, the world's first inhaled nano-antibody drug for the treatment of moderate and severe asthma, has completed the administration of the first patient in China's clinical phase I!
More
Total 51 123456